MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/bloodadvances.2022008282

Медицинская библиотека · Blood advances · 2023

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.

Zarnegar-Lumley Sara, Alonzo Todd A, Gerbing Robert B, Othus Megan, Sun Zhuoxin, Ries Rhonda E, Wang Jim, Leonti Amanda, Kutny Matthew A, Ostronoff Fabiana, Radich Jerald P, Appelbaum Frederick R, Pogosova-Agadjanyan Era L, O'Dwyer Kristen, Tallman Martin S, Litzow Mark, Atallah Ehab, Cooper Todd M, Aplenc Richard A, Abdel-Wahab Omar, Gamis Alan S, Luger Selina, Erba Harry, Levine Ross, Kolb E Anders, Stirewalt Derek L, Meshinchi Soheil, Tarlock Katherine

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study was to describe the prevalence, mutational profile, and prognostic significance of IDH mutations in AML across age. Our cohort included 3141 patients aged between <1 month and 88 years treated on Children's Cancer Group/Children's Oncology Group (n = 1872), Southwest Oncology Group (n = 359), Eastern Cooperative Oncology Group (n = 397) trials, and in Beat AML (n = 333) and The Cancer Genome Atlas (n = 180) genomic characterization cohorts. We retrospectively analyzed patients in 4 age groups (age range, n): pediatric (0-17, 1744), adolescent/young adult (18-39, 444), intermediate-age (40-59, 640), older (≥60, 309). IDH mutations (IDHmut) were identified in 9.2% of the total cohort (n = 288; IDH1 [n = 123, 42.7%]; IDH2 [n = 165, 57.3%]) and were strongly correlated with increased age: 3.4% pediatric vs 21% older, P < .001. Outcomes were similar in IDHmut and IDH-wildtype (IDHWT) AML (event-free survival [EFS]: 35.6% vs 40.0%, P = .368; overall survival [OS]: 50.3% vs 55.4%, P = .196). IDH mutations frequently occurred with NPM1 (47.2%), DNMT3A (29.3%), and FLT3-internal tandem duplication (ITD) (22.4%) mutations. Patients with IDHmut AML with NPM1 mutation (IDHmut/NPM1mut) had significantly improved survival compared with the poor outcomes experienced by patients without (IDHmut/NPM1WT) (EFS: 55.1% vs 17.0%, P < .001; OS: 66.5% vs 35.2%, P < .001). DNTM3A or FLT3-ITD mutations in otherwise favorable IDHmut/NPM1mut AML led to inferior outcomes. Age group analysis demonstrated that IDH mutations did not abrogate the favorable prognostic impact of NPM1mut in patients aged <60 years; older patients had poor outcomes regardless of NPM1 status. These trials were registered at www.clinicaltrials.gov as #NCT00070174, #NCT00372593, #NCT01371981, #NCT00049517, and #NCT00085709.

Для цитирования: Zarnegar-Lumley Sara, Alonzo Todd A, Gerbing Robert B, Othus Megan, Sun Zhuoxin, Ries Rhonda E, Wang Jim, Leonti Amanda, Kutny Matthew A, Ostronoff Fabiana, Radich Jerald P, Appelbaum Frederick R, Pogosova-Agadjanyan Era L, O'Dwyer Kristen, Tallman Martin S, Litzow Mark, Atallah Ehab, Cooper Todd M, Aplenc Richard A, Abdel-Wahab Omar, Gamis Alan S, Luger Selina, Erba Harry, Levine Ross, Kolb E Anders, Stirewalt Derek L, Meshinchi Soheil, Tarlock Katherine. Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis.. Blood advances. 2023. DOI: 10.1182/bloodadvances.2022008282.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.